glp-1 weight loss drugs Agonists Market Report, 2025-2030 GLP-1 Drugs from the Gray

Needle phobia affects an estimated 20-30% of the adult population, and the logistics of cold-chain storage, injection site management, and weekly self-administration limit the reach of these therapies to a fraction of the eligible patient population

The risk for obesity-related conditions, such as heart disease and sleep apnea, may also increase

Experiencing the loose stools that some people get, particularly with retatrutide

GLP-1RA (such as exendin-4) treatment can reduce the size of MI impacted cardiac volume in rats, inhibit ventricular dilation, myocardial fibrosis and hypertrophy in vivo [72]

However, the potential protective effects of these agents on recurrence and survival in BC patients are unclear